Completed
These studies have finished collecting, analyzing, and reporting data and are now archived.
-
CTN 143: Twice Daily Indinavir plus Ritonavir
An Open-Label, Randomized, 48-Week Study to Compare the Safety, Tolerability, and Surrogate Marker Activity of an Indinavir Sulfate (800 mg q8h) Regimen versus BID Indinavir Sulfate (800 mg q12h) plus Ritonavir (100 mg q12h) Regimen in HIV-Infected Individuals Having Previously Achieved Viral Load Suppression below the Limit of Detection with a Triple Antiretroviral Treatment Regimen…
-
CTN 131: ddI, d4T and DMP with or without Hydroxyurea (3D Study)
A Randomized Placebo-Controlled Study of the Safety and Efficacy of Efavirenz (DMP), Didanosine and Stavudine in Combination with or without Hydroxyurea in Antiretroviral-Naïve or -Experienced, HIV-Infected Patients:
-
CTN 119: Abacavir plus Amprenavir versus Nelfinavir
A Comparison of a Four-drug Regimen Comprised of 141W94, Abacavir (1592U89), and Combivir with a Three-drug Regimen Comprised of Nelfinavir and Combivir in Antiretroviral-Naïve, HIV-Infected Subjects. (Protocol 528/270 [NZTA4002])
-
CTN 118: Once Daily ADV plus ddI plus 3TC plus NVP (QD Study)
A Comparative Study of the Antiviral Effect of a Two or Three Times Daily Triple-Drug Regimen (Indinavir, Nelfinavir or Saquinavir [SGC], Lamivudine plus Zidovudine or Stavudine) against a Once Daily Regimen including Adefovir, Didanosine, Lamivudine and Nevirapine: Trial results
-
CTN 117: Intermittent Rifabutin for MAC and TB
A Pharmacokinetic Assessment of Intermittent Rifabutin Dosing Regimens in the Setting of Protease Inhibitor Therapy with a Combination of Ritonavir and Saquinavir in HIV-Infected Patients: Trial results
-
CTN 115: 141W94 (Amprenavir) versus Indinavir
A Phase III Trial to Compare the Safety and Antiviral Efficacy of 141W94 with Indinavir in Combination with Standard Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy in NRTI-Experienced, Protease Inhibitor (PI)-Naïve, HIV-1 Infected Patients. (Protocol PROA/B3006 [569/050]): Trial results
-
CTN 114: SCH 56592 versus Fluconazole for Thrush
A Multicentre, Randomized, Double-Blind, Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Multiple Doses of SCH 56592 versus Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients: Trial results
-
CTN 113: Adding 1592 (Abacavir) versus Adding Indinavir
A Phase III, Randomised, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IND in HIV-1 Infected, Antiretroviral Therapy-Naïve Subjects: Trial results
-
CTN 112: DMP 266 plus Indinavir
A Phase III, Double-Blind, Placebo-Controlled, Multicentre Study to Determine the Effectiveness and Tolerability of the Combination of DMP 266 and Indinavir versus Indinavir in HIV-Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy: Trial results
-
CTN 111: DMP 266 (Efavirenz) in Two- or Three-Drug Arm
A Phase III, Multicentre, Randomized, Open-Label Study to Compare Antiretroviral Activity and Tolerability of Three Combination Regimens (DMP 266 plus Indinavir, DMP 266 plus Zidovudine plus Lamivudine, Indinavir plus Zidovudine plus Lamivudine) in HIV-Infected Patients
-
CTN 110: Subcutaneous interleukin-2 in the setting of HIV infection
A randomized, open-label, phase III, international study of subcutaneous recombinant IL-2 (Proleukin®) in patients with HIV-1 infection and CD4+ cell counts u0026gt; 300 cells/mm3 (Evaluation of subcutaneous Proleukin in a randomized international trial; ESPRIT): Trial results
-
CTN 102: Nelfinavir versus Ritonavir (NvR)
A Randomized Trial of the Efficacy and Safety of Nelfinavir vs. Ritonavir added to Background Antiretroviral Nucleoside Therapy in HIV-Infected Individuals with CD4+ Cell Counts u0026lt; 100 mm3: Trial results
Careers
Interested in joining our team? Here are the current career opportunities with the CTN+ and our collaborators. For Fellowship opportunities, please visit our Postdoctoral Fellowship program page.v
Learn More